Iambic Therapeutics, Inc.
Biotechnology · SAN DIEGO, CA
BiotechnologySEC Form D
Iambic Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on April 8, 2026, reporting $27,769,668 raised toward a $49,999,996 offering.
Incorporated in Delaware and based in SAN DIEGO, CA, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Iambic Therapeutics, Inc. has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- Thomas MillerExecutive Officer · Director
- Fred ManbyExecutive Officer · Director
- Neil JosephsonExecutive Officer
- Michael SecoraExecutive Officer
- Jishnu BhattacharjeeDirector
- Evan RachlinDirector
- R. Jacob VogelsteinDirector
- Mary TagliaferriDirector
- William RastetterDirector
- Kurt von EmsterDirector
- Shalini SharpDirector
- Pete OlsonExecutive Officer
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$10.0MRaised